OncoTherapy Science, Inc.
4564オンコセラピー・サイエンス株式会社
Latest half-year results
First half · fiscal year to 2026-03 · filed 2025-11-10For the first half of the fiscal year to 2026-03: Revenue ¥0.4 billion (+91.9% YoY), Ordinary income ¥-0.5 billion, Net income ¥-0.6 billion.
| This period | Year on year | |
|---|---|---|
| Revenue | ¥432m | +91.9% |
| Ordinary profit | −¥494m | — |
| Net profit to owners | −¥555m | — |
From the securities report on EDINET, which states no forecast. History via /v1/companies/4564/earnings-releases.
Financials
Japan GAAP · consolidated · fiscal year to 2026-03-31- Revenue
- ¥809m
- Net income
- −¥911m
- ROE
- —
- Equity ratio
- 87.8%
- Dividend / share
- —
- Employees
- 46
| Fiscal year | Revenue | Net income | Total assets | Net assets | ROE | EPS | Operating CF |
|---|---|---|---|---|---|---|---|
| 2026-03-31 | ¥809m | −¥911m | ¥2,359m | ¥2,142m | — | ¥-2.77 | −¥923m |
| 2025-03-31 | ¥750m | −¥815m | ¥1,155m | ¥729m | — | ¥-3.12 | −¥815m |
| 2024-03-31 | ¥610m | −¥1,288m | ¥867m | ¥354m | — | ¥-6.05 | −¥1,228m |
| 2023-03-31 | ¥1,135m | −¥1,119m | ¥1,511m | ¥855m | — | ¥-5.81 | −¥795m |
| 2022-03-31 | ¥1,154m | −¥2,572m | ¥2,685m | ¥1,980m | — | ¥-13.72 | −¥2,073m |
Indicators
Computed by us from filings · fiscal year to 2026-03-31| Metric | Value | Percentile among listed companies |
|---|---|---|
| ROE, % | — | — |
| Ordinary margin | -1.0461 | 1.1 |
| Equity ratio, % | 87.8 | 97.1 |
| Revenue growth | 0.078 | 62.2 |
| Net income growth | -0.117 | 27.3 |
| Operating cash flow / assets | -0.3911 | 1.1 |
Via /v1/companies/4564/indicators. Descriptive figures, not a rating and not investment advice.
From other filings
As the company states themSegments, votes and tender offers
Stated in EDINET filings/v1/companies/4564/segments/v1/companies/4564/votingOwnership changes
All companies →- 2026-10-16
individual filer filed a correction to a 5% report on OncoTherapy Science, Inc. (4564).
- 2026-10-16
individual filer filed a correction to a 5% report on OncoTherapy Science, Inc. (4564).
- 2026-10-16
individual filer filed a correction to a 5% report on OncoTherapy Science, Inc. (4564).
- 2026-09-11
individual filer reduced holdings in OncoTherapy Science, Inc. (4564) to 6.49% from 6.50%.
- 2026-09-11
individual filer reduced holdings in OncoTherapy Science, Inc. (4564) to 6.05% from 6.49%.
- 2026-06-15
Long Corridor Asset Management Limited cut holdings in OncoTherapy Science, Inc. (4564) to 4.63% from 5.81%, below the 5% threshold.
- 2026-06-10
Long Corridor Asset Management Limited reduced holdings in OncoTherapy Science, Inc. (4564) to 5.81% from 7.04%.
- 2026-04-21
Long Corridor Asset Management Limited reduced holdings in OncoTherapy Science, Inc. (4564) to 7.04% from 8.17%.
- 2026-04-20
Long Corridor Asset Management Limited reduced holdings in OncoTherapy Science, Inc. (4564) to 8.17% from 9.59%.
- 2026-04-13
Long Corridor Asset Management Limited raised holdings in OncoTherapy Science, Inc. (4564) to 9.59% from 9.36%.
Trades by 5% holders
From the 60-day trade tables in 5% reports| Holder | Period | Net shares | Net % of shares | Avg. filed price | Range |
|---|---|---|---|---|---|
| Long Corridor Asset Management Limited | 2023-04-03 – 2026-06-12 | +111,204,000 | +29.43pt | ¥27.57 | ¥15–38 |
Net shares and the average are our calculations. Prices are filed prices as stated by the filer, mostly for off-market trades; they are not market prices. Stock lending, custody transfers and option exercises are excluded from net shares. Every row via /v1/companies/4564/trades.
5% filings
Large shareholding reports on 4564| Filed | Filer | Stake | Change | Stated purpose |
|---|---|---|---|---|
| 2026-10-16 | individual filer | 6.05% | −0.44pt | — |
| 2026-10-16 | individual filer | 6.49% | 0.00pt | — |
| 2026-10-16 | individual filer | 6.49% | −0.01pt | — |
| 2026-09-11 | individual filer | 6.49% | −0.01pt | — |
| 2026-09-11 | individual filer | 6.49% | 0.00pt | — |
| 2026-09-11 | individual filer | 6.05% | −0.44pt | — |
| 2026-06-15 | Long Corridor Asset Management Limited | 4.63% | −1.18pt | pure investment |
| 2026-06-11 | Long Corridor Asset Management Limited | 5.81% | 0.00pt | pure investment |
| 2026-06-10 | Long Corridor Asset Management Limited | 5.81% | −1.23pt | pure investment |
| 2026-04-21 | Long Corridor Asset Management Limited | 7.04% | −1.13pt | pure investment |
Cross-shareholdings
From the annual report's status of shareholdings- Listed strategic holdings
- — issues
- Book value
- —
- Sold in the year
- — — issues
- Bought in the year
- — — issues
- Mutual, both reports
- 0
- Held by listed cos.
- 1
Held by: Shionogi & Co.,Ltd. 4507
Purposes, all holdings and mutual flags via /v1/companies/4564/cross-holdings. Share changes include stock splits.
Major shareholders
As of fiscal year end 2026-03-31| Shareholder | Shares | Ratio |
|---|---|---|
| individual holder | 12,511,000 | 3.26% |
| 楽天証券株式会社共有口 | 9,155,500 | 2.39% |
| 特定有価証券信託受託者株式会社SMBC信託銀行 | 7,300,000 | 1.90% |
| individual holder | 5,850,000 | 1.52% |
| 野村證券株式会社 | 3,781,200 | 0.99% |
| individual holder | 3,000,100 | 0.78% |
| individual holder | 2,943,000 | 0.77% |
| individual holder | 2,850,000 | 0.74% |
| individual holder | 2,553,000 | 0.67% |
| individual holder | 2,487,400 | 0.65% |
Get this as JSON
GET /v1/companies/4564
GET /v1/companies/4564/financials
GET /v1/companies/4564/details
GET /v1/companies/4564/segments
GET /v1/companies/4564/voting
GET /v1/companies/4564/tender-offers
GET /v1/companies/4564/indicators
GET /v1/companies/4564/earnings-releases
GET /v1/events?ticker=4564
GET /v1/companies/4564/trades
GET /v1/companies/4564/cross-holdings
GET /v1/companies/4564/brief